This Hims & Hers Move Could Destroy Competitors

By Travis Hoium – Mar 21, 2026 at 6:00AM ESTKey PointsThe recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers. The fastest GLP-1 launch in history could be boosted by a wider distribution funnel. This could bring growth back to Hims & Hers in 2026. Hims & Hers (HIMS 8.78%) has had a rough go of it in 2026, but a recent deal with Novo Nordisk (NVO 1.43%) may bring the company's operations back to life. The Wegovy pill is one of the products coming to Hims & Hers, and we now know details of what that launch will look like, and it could make this a high-growth stock by the end of 2026. In this video, I explain why this launch is so exciting. *Stock prices used were end-of-day prices of March 18, 2026. The video was published on March 20, 2026. Read NextMar 21, 2026 •By Lee SamahaHere's Why Grail Shares Crushed the Market This WeekMar 20, 2026 •By David Jagielski, CPADown Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?Mar 20, 2026 •By Prosper Junior BakinyIs CRISPR Therapeutics Stock a Buy Now?Mar 20, 2026 •By Prosper Junior BakinyBest Healthcare Stocks to Buy After the Market PullbackMar 20, 2026 •By Prosper Junior BakinyMy Top 3 Drug Stocks for March 2026Mar 20, 2026 •By James Halley2 Healthcare Stocks to Buy Before They Get Bought OutAbout the AuthorTravis Hoium is a contributing Motley Fool stock market analyst covering solar energy, technology, and growth stocks.

Before The Motley Fool, Travis was a mechanical engineer at 3M and founded a virtual reality company. He holds a bachelor’s degree in mechanical engineering and a master’s degree in business administration from the University of Minnesota.TMFFlushDrawX@travishoiumStocks MentionedNovo NordiskNYSE: NVO$36.55(-1.43%)-$0.53Eli LillyNYSE: LLY$905.63(-1.29%)-$11.87Hims & Hers HealthNYSE: HIMS$22.04(-8.78%)-$2.12*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.